Enhanced murine contact hypersensitivity by depletion of endogenous regulatory T cells in the sensitization phase.
Tetsuya
T
Honda
Atsushi
A
Otsuka
Hideaki
H
Tanizaki
Yusuke
Y
Minegaki
Keisuke
K
Nagao
Herman
H
Waldmann
Michio
M
Tomura
Shohei
S
Hori
Yoshiki
Y
Miyachi
Kenji
K
Kabashima
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000941:Antigens / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D049109:Cell Proliferation; D003713:Dendritic Cells / Q000276:immunology; D003877:Dermatitis, Contact / Q000276:immunology*; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000941:Antigens; D000074323:Alemtuzumab; D007371:Interferon-gamma